Floatz logo

GSK-2256294A

Obesity

Vanderbilt University Medical CenterSmall moleculePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
59/ 100

Competitive context

575 Active assets in the Obesity cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Tirzepatide
LABORATORIOS INDUFAR
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB

View all 50 →

Same molecule, other indications

GSK-2256294A is also rated in:

diabetes mellitusDormant
B
Indicative ·
57 / 100
View asset →
endocrine system disorderDormant
B
Indicative ·
57 / 100
View asset →
glucose metabolism diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →